Gilead Sciences ($GILD) has seen its stock price grow more than 80% this year on a number of positive developments. Now it will pony up half a billion dollars to buy a Canadian company to move further into oncology drugs.
With its stellar hep C program in the spotlight, Gilead Sciences is expanding its R&D efforts with plans to build on to its research operations in Canada and hire dozens of new scientists. Gilead has snagged 10 acres in an Edmonton biotech park and has blueprinted a 45,000-square-foot facility to house another 80 researchers working on process chemistry and analytical development of new drug substances.
For all of the attention Gilead's Truvada has gotten as the first FDA-approved vaccine to be used to prevent HIV infections, there is little expectation that it will get widespread use in the U.S.
Gilead Sciences ($GILD) hardly had time to celebrate FDA's approval of its new HIV treatment Stribild, aka the Quad. The company announced Stribild's price tag--$28,500--and critics pounced.
The FDA handed Gilead Sciences an approval for its four-in-one HIV drug Quad, extending its blockbuster franchise with a new drug that is expected to find a quick uptake among patients. Next step: Pricing the drug, which could trigger a backlash among payers and patients.
A U.S. advisory panel may recommend before the end of the year that primary care doctors start routine testing for HIV, a shift that if it occurs, has huge implications for drugmakers with HIV meds.
The FDA has put off by three months its decision on whether the Gilead Sciences drug Truvada can be used as the first preventative HIV treatment, but analysts don't see it as a sign of trouble.
The four-in-one pill for HIV won support from an FDA advisory committee Friday, bolstering the Foster City, CA-based company's efforts to gain approval of the drug and maintain its top position in the market for HIV and AIDS drugs.
It is two down and one to go for Truvada, the Gilead Sciences ($GLD) HIV medication. An FDA advisory panel, following the lead of the agency staff, recommended 19-3 that the drug be prescribed to people at high risk as a preventive against HIV infection.
The kidney damage could warrant monitoring of patients taking the drug, the FDA staff briefing said, according to Bloomberg.